MRA third party guidance
This article was originally published in The Gray Sheet
European conformity assessment bodies reviewing a 510(k) submission or conducting a quality system evaluation in accordance with the U.S./EU mutual recognition agreement may not use personnel who were employed within the last twelve months by the sponsor or inspected firm, FDA says in a Jan. 6 updated version of its guidance document on third-party programs under the MRA. The extra condition regarding the prevention of conflicts of interest is one of the few changes to the document
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.